Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation: A Single Technology Appraisal. Evidence Review Group Report to NICE
| Data(s) |
02/06/2016
23/09/2015
02/06/2016
2015
|
|---|---|
| Resumo |
1.1 Edoxaban is recommended, within its marketing authorisation, as an option for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation with one or more risk factors, including: congestive heart failure hypertension diabetes prior stroke or transient ischaemic attack age 75 years or older |
| Identificador |
NICE technology appraisal guidance (TA355), (September 2015) 978-1-4731-1440-1 |
| Idioma(s) |
en |
| Publicador |
National Institute for Health and Care Excellence (NICE) |
| Palavras-Chave | #Guidance #Edoxaban #Stroke #Prevention #Systemic embolism |
| Tipo |
Other |
